Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2018 Earnings Results

Crinetics Pharmaceuticals Misses on EPS, Stock Down 1.78%

Crinetics Pharmaceuticals reported a significant loss per share, which contributed to a 1.78% decline in its stock price. The lack of revenue figures and guidance may have raised concerns among investors about the company's short-term outlook. Overall, the market reaction reflects uncertainty regarding Crinetics' current financial health and future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-2.41	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed caution regarding the company's performance. They emphasized their commitment to long-term goals without providing specific guidance.

Management did not provide specific revenue figures or guidance for the upcoming quarters.

The company remains focused on its long-term strategy despite the current challenges.

Crinetics Pharmaceuticals Misses on EPS, Stock Down 1.78%

Key numbers

Management commentary

Crinetics Pharmaceuticals, Inc.

More earnings this week

Crinetics Pharmaceuticals Misses on EPS, Stock Down 1.78%

Key numbers

Management commentary